Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 10/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879101 | 0.95 | GRIN2B (0.35) | GRIN2BALDH1A1KMT2AGAASMN1; SMN2 | |
| SCHEMBL4868456 | 0.91 | ALDH1A1 (0.39) | GRIN2BALDH1A1KMT2AGAASMN1; SMN2 | |
| SCHEMBL4877300 | 0.88 | GRIN2B (0.41) | GRIN2BALDH1A1KMT2AGAASMN1; SMN2 | |
| SCHEMBL4871889 | 0.88 | GRIN2B (0.41) | GRIN2BALDH1A1KMT2AGAASMN1; SMN2 | |
| SCHEMBL4868731 | 0.87 | GRIN2B (0.36) | GRIN2BALDH1A1KMT2AGAASMN1; SMN2 | |
| SCHEMBL4876718 | 0.87 | ALDH1A1 (0.39) | GRIN2BALDH1A1KMT2AGAASMN1; SMN2 | |
| SCHEMBL4875238 | 0.87 | ALDH1A1 (0.39) | GRIN2BALDH1A1KMT2AGAASMN1; SMN2 | |
| SCHEMBL4876216 | 0.87 | KCNH2 (0.39) | GRIN2BALDH1A1KMT2AGAASMN1; SMN2 | |
| SCHEMBL4874030 | 0.87 | KCNH2 (0.39) | GRIN2BALDH1A1KMT2AGAASMN1; SMN2 | |
| SCHEMBL4871957 | 0.86 | ALDH1A1 (0.35) | GRIN2BALDH1A1KMT2AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | GRIN2B 3420/4885ALDH1A1 1357/4885KMT2A 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.